P2P Call Guide

How to Win a P2P Call for Biologic Therapy (Autoimmune) Denied by UHC

Payer-specific strategy, medical necessity arguments, and the exact phrases to use when UnitedHealthcare denies Biologic Therapy (Autoimmune) (CPT J0135, J1745, J0717).

Why UHC Denies Biologic Therapy (Autoimmune)

Step therapy not completed (conventional DMARDs first)

Prior biologic trial not documented

Biosimilar required before brand-name biologic

Know UnitedHealthcare's Criteria

UHC uses InterQual criteria and their own Clinical UM Guidelines (CG series). Medical directors are typically accessible for P2P within 5 business days.

Key policies to know:

  • Requires eviCore for MSK and advanced imaging prior auth
  • Clinical UM Guidelines (CG series) are publicly available online
  • Prior auth through Optum/UHG portal
  • Known for strict step therapy requirements on biologics

UHC's Specific Approach to Biologic Therapy (Autoimmune)

Applicable Policy

UHC Pharmacy Clinical UM Guidelines (varies by drug -- e.g., Humira, Enbrel, Remicade)

How UHC Typically Denies This

UHC has strict step therapy: methotrexate + one conventional DMARD must fail before biologics for RA. For IBD, conventional therapy failure is required. They also mandate biosimilar-first policies for many biologics.

Your Strategy for This Payer

Know the specific step therapy requirements for your patient's diagnosis. Document failure of each step therapy agent with specific reasons (inadequate response, adverse effects, contraindication). If biosimilar is required, have a clinical reason for brand preference.

Key Phrase to Use on the Call

"The patient has failed [methotrexate at X dose for Y months] and [second DMARD] with documented [inadequate response/adverse effects], meeting UHC's step therapy requirements for biologic initiation."

Building Your Medical Necessity Argument

Document failure, intolerance, or contraindication to step therapy agents

Note disease activity scores (DAS28, CDAI, PASI)

If biosimilar switch requested, document clinical reason for brand

Reference comorbidities that limit alternative treatments

P2P Call Tips for UHC

Reference UHC's own Clinical UM Guideline number (e.g., CG-SURG-71)

UHC medical directors respond well to InterQual criteria language

Be specific about which InterQual subset applies

Have the CG policy number ready -- shows you've done your homework

Guidelines to Reference

  • ACR Guidelines for Rheumatoid Arthritis Treatment
  • AGA Guidelines for Biologic Therapy in IBD
  • AAD Guidelines for Biologic Therapy in Psoriasis

Relevant CPT Codes

CPT J0135CPT J1745CPT J0717

Specialty: Rheumatology / Gastroenterology / Dermatology

Want the full strategy?

The P2P Playbook covers payer-specific approaches for Biologic Therapy (Autoimmune) denied by UHC -- plus 15 denial objections with word-for-word responses, what reviewers are actually thinking, and the 60-second prep framework. Written by a medical director who reviewed cases for major payers.

Get The P2P Playbook -- $39

Get a personalized P2P script in 60 seconds

Enter your specific case details and our AI generates a structured prep script tailored to UHC's criteria.

More Biologic Therapy (Autoimmune) P2P Guides

More UHC P2P Guides